Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi… Ended

2023-506301-20-00 Tuberous Sclerosis Complex (TSC) 2024-04-15
An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr… Ended

2024-517959-12-00 Relapsed/refractory B cell precursor acute lymphoblasti 2024-04-11
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihis… Ended

2023-505446-25-00 Chronic Spontaneous Urticaria 2024-03-20
Allogenic mesenchymal stem cell intraarticular injection for knee osteoarthritis therapy, an RCT explorative mode-of-action study Ended

2023-506088-33-01 knee osteoarthritis 2024-03-07
A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants… Ended

2022-502465-18-00 Advanced or metastatic breast cancer 2024-02-15
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With … Ended

2022-502231-19-00 ER+/HER2- Advanced or Metastatic Breast Cancer 2024-01-02
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of Vepdegestrant (ARV-471) in Combination With Other Medicines… Ended

2022-502228-34-00 ER +/HER2- Advanced or Metastatic Breast Cancer 2023-12-27
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended

2022-502010-85-00 Non-Squamous Non-Small Cell Lung Cancer 2023-12-20
Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended

2024-514876-41-00 Higher-risk myelodysplastic syndromes untreated and ine 2023-12-06
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib in G12C NSCLC Patients (RAMP203) Ended

2023-505107-24-00 Non-small cell lung cancer 2023-11-14
Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head a… Ended

2024-516779-33-00 Carcinoma 2023-11-08
A phase 1/2 study of SLN124 in patients with Polycythemia Vera Ended

2023-503544-13-00 Polycythemia Vera 2023-11-02
A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokine… Ended

2023-504215-32-00 Overweight and obesity 2023-09-28
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I). Phase I/II clinical study to evaluate the safety and… Ended

2022-501086-41-00 Leukocyte Adhesion Deficiency-I (LAD-I) 2023-09-15
A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed K… Ended

2022-502275-39-00 multiple myeloma 2023-05-19
Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in paediatric subjects with Optic Pathway Glioma (OPG). A … Ended

2024-515753-16-00 Optic Pathway Glioma (OPG) 2023-05-18
Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma Ended

2022-500687-35-00 Refractory Mantle Cell Lymphoma 2023-04-04
PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR A… Ended

2024-515492-34-00 Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TN 2023-03-30
CAPTIRALL _ Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblasti… Ended

2024-514345-11-00 children, adolescents and young adults with Acute Lymph 2023-03-15
An Open-Label Phase 1/2 Trial to Evaluate the Safety, Tolerability, and Efficacy of MORAb 202 in Subjects with Selected Tumor Types. Ended

2023-506868-14-00 Solid tumors in 4 tumor types: platinum resistant ovari 2023-02-28
An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended

2023-510081-27-00 Systemic Lupus Erythematosus. 2023-02-28
Study to evaluate the long-term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and… Ended

2024-510946-15-00 Geographic atrophy (GA) secondary to age-related macula 2022-12-08
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMB… Ended

2024-516147-32-00 Relapsed/refractory multiple myeloma 2022-12-06
Study of the safety and efficacy of treatment venetoclax + azacitidine and donor lymphocyte infusion in patients with MDS or AML in relapse … Ended

2024-514877-23-00 Myelodysplastic syndromes or Acute Myeloid Leukemia 2022-11-23